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Using imputation to provide
harmonized longitudinal measures
of cognition across AIBL and ADNI
Rosita Shishegar1,2*, Timothy Cox1, David Rolls1, Pierrick Bourgeat1, Vincent Doré1,3,
Fiona Lamb3, Joanne Robertson4, Simon M. Laws5,6,7, Tenielle Porter5,6,7, Jurgen Fripp1,
Duygu Tosun8, Paul Maruff9, Greg Savage10, Christopher C. Rowe3,11, Colin L. Masters4,
Michael W. Weiner8, Victor L. Villemagne3,12 & Samantha C. Burnham1
To improve understanding of Alzheimer’s disease, large observational studies are needed to increase
power for more nuanced analyses. Combining data across existing observational studies represents
one solution. However, the disparity of such datasets makes this a non-trivial task. Here, a machine
learning approach was applied to impute longitudinal neuropsychological test scores across two
observational studies, namely the Australian Imaging, Biomarkers and Lifestyle Study (AIBL) and
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) providing an overall harmonised dataset.
MissForest, a machine learning algorithm, capitalises on the underlying structure and relationships
of data to impute test scores not measured in one study aligning it to the other study. Results
demonstrated that simulated missing values from one dataset could be accurately imputed, and
that imputation of actual missing data in one dataset showed comparable discrimination (p < 0.001)
for clinical classification to measured data in the other dataset. Further, the increased power of the
overall harmonised dataset was demonstrated by observing a significant association between CVLT-II
test scores (imputed for ADNI) with PET Amyloid-β in MCI APOE-ε4 homozygotes in the imputed
data (N = 65) but not for the original AIBL dataset (N = 11). These results suggest that MissForest can
provide a practical solution for data harmonization using imputation across studies to improve power
for more nuanced analyses.
Aging populations are increasing the incidence of Alzheimer’s disease (AD) meaning that current health and
economic frameworks will be overwhelmed without a cure or delay to the onset of disease. Thus, there exists an
unprecedented challenge for understanding and preventing this disease. Alzheimer’s disease is a progressive,
neurodegenerative disease characterized by neurodegeneration, synaptic loss, the accumulation of extracellular
amyloid plaques and intracellular tau neurofibrillary t angles1,2. The major genetic risk factor for AD is the ε4
allele of apolipoprotein E (APOE)3, which has been consistently associated with cortical and subcortical grey
matter atrophy and episodic memory d
 ecline4.
To increase understanding of the relationships between AD biomarkers and clinical disease progression, as
well as the extent to which these relationships may be influenced by demographic, clinical or genetic factors,
studies will require very large samples. This need will be increased if these factors are only present in small proportions of the population or if the magnitude of first or second interactions are small. One way to achieve additional power from existing data would be to combine data from existing studies such as the Australian Imaging,
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Biomarkers and Lifestyle (AIBL) Study of Ageing and Alzheimer’s Disease Neuroimaging Initiative (ADNI). In
addition to increased statistical power, combining data across studies should also decrease bias due to sampling
error, and improve the external validity of fi
 ndings5,6. Harmonisation would further extend the utility of existing
datasets7 and increase opportunities for multi-centre research c ollaborations8–11.
Despite these advantages, combining multiple existing datasets is not a common practice or trivial task due
to differences in the study protocols. For example, different neuropsychological test batteries are administered
for monitoring cognitive performance, measuring clinical disease progression and informing classification of
clinical status (i.e., mild cognitive impairment (MCI) or dementia)12,13. While the different prospective AD
studies largely converge in their neuropsychological test batteries on detailed measurement of memory, they
differ in a number of ways including: (1) the number of other domains assessed, (2) the test paradigms used to
measure specific domains (e.g. measurement of verbal or visual memory), (3) where the same test paradigm is
used by both studies (e.g. list learning) it can be operationalized using different standardized tests (e.g. 15-word
unstructured Rey Auditory Verbal Learning Test (RAVLT)14 in ADNI and the 16-word 5 trial T implicitly structured California Verbal Learning Test-Second edition (CVLT-II)15 in AIBL), (4) the number of scores derived
from the different standardized tests and (5) their naming conventions.
In addition to variation in test scores, the design of AD prospective longitudinal studies is also different. For
example, AIBL and ADNI use different retest intervals, have existed for different time periods and are composed
of participants who have been evaluated from study inception as well as others that have joined later as part of
multiple enrichment strategies.
In the context of data aggregation the term harmonization is defined as the process of transforming data
from related outcomes to have similar response or scaling and thereby allow data from multiple studies to be
integrated16,17. Statistical harmonization can be predominantly classified into three general m
 ethodologies18. First,
different but related test scores can be combined across datasets by using a simple linear or z-transformation16,19,20.
This approach of standardizing or normalizing scores generates data distributions that are unit-free thereby
allowing outcomes from theoretically similar tests in different studies to be combined. Such methods require
that the same underlying information is collected by similar tests and the strategy is not suitable for harmonising
data with discrete v alues21–24, non-normal distributions or ceiling/floor e ffects18. Second, latent variable models
can be utilised to determine underlying latent factors from a set of multiple test scores21. These models require
common ‘anchor’ variables and assume that the measured test scores provide the same underlying information
across studies that is captured by the latent c onstruct21. Thirdly, imputation or maximum likelihood estimation
can be used to impute values for a test not administered in one dataset that is administered in another. In this
methodology test scores for the dataset that did not administer the test are considered missing in the joined
dataset25–27 and imputation strategies are employed to impute the missing test scores25–27.
The present study proposes a new approach which uses a machine learning algorithm to impute and harmonize cognitive test scores across studies, as an extension to existing imputation methods of harmonization.
The underlying structures and relationships of the measured d
 ata21 are exploited to impute cognitive test scores
in one dataset where the test was not administered. This aligns that dataset to another dataset in which the
test was measured, resulting in harmonized data across the two datasets. The estimation of the unmeasured
test scores using an iterative imputation method based on Random f orest28, called “MissForest”29 is proposed.
Random forest is an advanced non-parametric machine learning algorithm which is able to handle mixed-type
data (discrete, continuous and categorical variables) as well as data with a non-linear structure or that is nonnormally distributed30. This investigation validates the proposed harmonization through imputation method
using simulated missing values from two tests administered in both AIBL and ADNI datasets. Also, the extent
to which the validity of the imputation holds is tested using different percentages of missing data. Further, the
effectiveness of the method is demonstrated by imputing actual missing data for test scores only measured in
one dataset. Finally, the utility of harmonised data to increase power in nuanced analyses is demonstrated by
evaluating the relationship between cognition and PET Amyloid-β in APOE ε4-homozygotes with mild cognitive
impairment (a small, very specific, sample of participants).

Materials and methods

Datasets. This study utilized neuropsychological, clinical, demographic and neuroimaging data collected as
part of the AIBL and ADNI studies. The process of recruitment and enrolment in each of these studies has been
described in detail elsewhere (ADNI31 and A
 IBL32,33 http://www.adni-info.org/index) and in the “Supplementary materials”.
Briefly, in AIBL, individuals classified clinically with mild cognitive impairment (MCI) or Alzheimer’s disease (AD) dementia were recruited from primary-care physicians or tertiary Memory Disorders Clinics at two
study centres in Melbourne, Victoria and Perth, Western Australia. Cognitively normal (CN) older adults were
recruited through advertisement or from spouses of participants in the study, at the same centres. The dataset
contains data about neuroimaging, biomarkers, lifestyle, clinical information, and neuropsychological assessments. The follow-up data were collected every 18 months (18, 36, 54, 72 and 90 months)31. Note not all participants completed all the evaluations. Written informed consent was obtained from all participants. Approval for
the study was obtained from the human research ethics committees of Austin Health, St Vincent’s Hospital, Edith
Cowan University, and Hollywood Private Hospital. All methods were carried out in accordance with relevant
guidelines and regulations and all participants or legal guardian(s)/legally authorized representatives gave their
informed consent (for more details, see Ellis et al.31, https://aibl.csiro.au).
ADNI is a multi-centre longitudinal neuroimaging study, launched by the National Institute on Aging, the
National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies and non-profit organizations in 2004. The dataset includes data from neuroimaging,
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biomarkers, clinical information, and neuropsychological assessments, as previously d
 escribed32,33. The ADNI
participants were followed prospectively, with follow-up time points at 3 months, 6 months, then every 6 months
until up to 156 months. Note not all participants completed all the evaluations. A committee on human research
at each participating institution approved the study protocol, and all participants or legal guardian(s)/legally
authorized representatives gave their informed consent. All methods were carried out in accordance with relevant
guidelines and regulations.

Inclusion and exclusion criteria. In this study, clinical measures and neuropsychological tests that were

common across AIBL and ADNI and that had less than 50% missing data in each of the respective datasets were
included. For example, whilst Digit Span and Digit Symbol-Coding were measured in both datasets, more than
50% of the observations were missing in one of the original datasets, therefore they were excluded. To demonstrate the utility of the method, two tests not common across the datasets were also included, namely: the RAVLT
from ADNI and the CVLT-II from AIBL. All included clinical and cognitive test scores, alongside their variable
names in ADNI and AIBL datasets and their percentage of missingness are listed in Table S1.
We excluded a participant’s measurements at a specific time point if the clinical classification was missing
and the classification could not be determined using the clinical classification of the participant at an adjacent
timepoint. Further, a participant’s measurements at a specific time point were excluded if there were less than
three completed neuropsychological test measurements for that time point.
This study included 1805 AIBL participants (CN = 1180, MCI = 297 and AD = 328), aged 72.42 ± 7.64 years
with 777 males at baseline, and 2122 ADNI participants (CN = 791, MCI = 962, AD = 369), aged 73.32 ± 7.21 years
with 1129 males at baseline.

Joined dataset. A joined dataset was formed combining the AIBL and ADNI datasets in long format, where

each row represented a single time point per subject. All missing data were coded as “NA”, this including data
missing at random as well as systematically missing data (e.g. from the CVLT-II and RAVLT)18.
Cognitive tests used to provide a joined dataset across AIBL and ADNI included subtests from: California
Verbal Learning Test-Second edition (CVLT-II)15, Rey Auditory Verbal Learning Test (RAVLT)14, and Logical
Memory (LM) I and II (WMS; Story A only), 30-item Boston Naming Test (BNT)34, Digit Span and Digit SymbolCoding subtests of the Wechsler Adult Intelligence Scale-Third edition (WAIS-III)35.
Time-dependent variables were defined as rate of change for each of the clinical and cognitive tests, calculated
as the difference in test scores between the current and previous time point divided by the time elapsed between
those two time points. Given that in the long format longitudinal data at each row is a single time point per subject, the time-dependent variables represent a longitudinal feature of each test score for a specific subject. These
variables were included as predictors in the models. Time was calculated as the number of months since baseline.
The final joined dataset included 39 columns. Variables incorporated in the joined dataset included: (a)
identifiers: participant ID and dataset ID; (b) demographic measurements: age, sex, years of education, clinical
classification (CN, MCI and AD), and a genetic risk factor (carriage of the APOE-ɛ4 allele3); (c) clinical tests:
Clinical Dementia Rating (CDR), and Mini-Mental State Examination (MMSE)36; (d) 14 cognitive test scores;
and (e) time-dependent variables calculated for clinical tests and cognitive scores.

Data preparation. Due to differences in naming conventions between ADNI and AIBL it was necessary to
adopt a single variable name for the joined dataset. Table S1 lists the original name of the study variables from
AIBL and ADNI, the description of the test scores and the names used for the variables in the joined dataset.
Further, data included in the joined dataset were modified to ensure the same representation and data type
across the studies; this included: (1) converting the continuous values of the years of education in ADNI to
ordinal values with four intervals (< 9, 9–12, 13–15, 15+) as in AIBL, (2) converting genetic risk factors data
which are presented with characters in AIBL into categorical values as in ADNI, (3) converting gender in AIBL
from data type characters to categorical values. The age for AIBL dataset was also calculated using date of birth
and the date cognitive tests were administered.
PET Aβ‑amyloid for the case study. A subset of AIBL subjects (N = 1042) underwent Aβ-amyloid positron emission tomography (PET) imaging using either 11C-Pittsburgh compound-B (11C-PiB), 18F-NAV4694
(NAV), 18F-florbetaben (FBB), 18F-florbetapir (FBP) or 18F-flutemetamol (FLUTE). A subset of ADNI subjects
(N = 1565) underwent Aβ-amyloid PET studies with either FBP or FBB. The AIBL PET images were smoothed
to a uniform 8 mm full width half-maximum point spread function to match the PET pre-processing done in
ADNI37. All PET images were spatially normalized with SPM8, using the prescribed Centiloid pipeline38. Then a
tissue ratio, termed SUV ratio (SUVR), was computed using the ratio of the PET retention computed inside the
neocortical Centiloid mask and the whole cerebellum. The SUVR was then transformed into Centiloids using
each tracer’s respective linear t ransform39. Smaller subsets of the data from AIBL (33 observations from N = 11
subjects) and ADNI (108 observations from N = 54 subjects) including APOE-ε4/ε4 individuals with MCI were
used to investigate the influence of the levels of Aβ-amyloid on memory performance.
Statistical analysis and process of imputation. Baseline differences in demographic variables and
months of follow-up between AIBL and ADNI datasets were analysed using a t-test for continuous variables
with normal distribution, Mann–Whitney U-test for continuous variables with non-normal distribution, and
χ2 for categorical variables.
After joining the AIBL and ADNI datasets together, all missing data coded as ‘NA’, which included test scores
not measured for one dataset (systematic missing) and data missing at random, were imputed using MissForest40,
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a non-parametric, iterative imputation method based on Random forests28. For further details on the MissForest
approach are provided by Stekhoven et al.40. Our model parameters included the 39 variables described in the
previous section except for the participant ID and dataset ID (AIBL, ADNI). Note that the dataset ID was used
later in validation steps but was not shown to the prediction models.
Using notation similar to Stekhoven et al.40, let X = (X1, X2, …, Xp) to be a r × p-dimensional joint AIBL-ADNI
dataset. For each outcome variable X
 k, iobs indicates the indices of the subjects with observed values and imis
indicates the indices of the subjects with missing values. yobs are the observed values of Xk, and ymis are the missing values of variable X
 k. Xobs indicates a data matrix including the subjects with i obs indices and all the variables
except for X
 k. Xmis is a data matrix including the subjects with imis indices and all the variables except for Xk.
For instance, to estimate CVLT-II test scores, yobs represent the observed values of a CVLT-II score from AIBL,
and ymis represents values that are randomly missing from AIBL as well as the completely missing values from
ADNI. MissForest required an initial value for missing data, here the median of the measured data in the joined
dataset was used for continuous as well as discrete variables and for categorical variables the category with the
highest frequency was used. MissForest then fit the random forest model with response yobs and predictors Xobs
(including the rest of neuropsychological test scores as well as clinical and demographic measures) to extract the
underlying relationships between CVLT-II and the other observed data in X
 obs. Using this final, trained MissForest model and the other observed data in Xmis, the missing values of CVLT (ymis) were imputed. The imputed
data were then defined as the initial estimates and the procedure was repeated until the difference between the
input and output estimates was sufficiently small (stopping criterion40).
We used the M
 issForest40 package in R
 29, which is an implementation of the Random Forest algorithm28
that iteratively creates non-parametric imputations of each variable. To have high precision the number of trees
was set to the default value of 100. The number of iterations was chosen to be 10 if the stopping criterion was
not already met. However, it has been shown that the algorithm normally reaches the stopping criterion in five
iterations40. Since the neuropsychological test scores LMII and CVLT-II are integer values, after the imputation
the estimated scores were rounded to the nearest integer.

Method validation by simulating missing data. To evaluate the efficacy of the method and validate its
utility, LMII and MMSE tests measured across both AIBL and ADNI were selected as outcome variables where
a proportion of the data was simulated as missing. Here, let n and m be number of subjects with an observed
outcome variable (e.g. LMII) in AIBL and ADNI datasets, respectively. Given the larger size of observations in
ADNI compared to AIBL (m ~ 1.7*n), a subsample of ADNI with the same size as AIBL, herein called ADNIsub,
was used for the validation steps to ensure comparable results across the evaluations. Also, in order to simplify
the validation, the CVLT-II and RAVLT scores, only observed in one dataset, were excluded from these validation steps. The following two validation approaches were undertaken:
First validation approach: to provide an understanding of the impact of the different underlying structures and
relationships in AIBL and ADNI, the differences between estimating missing data using observed data from the
same dataset (i.e. ADNI data predicting missing ADNI data) as well as a different dataset (i.e. AIBL data predicting missing ADNI data), which represents the proposed harmonization approach were evaluated. The LMII (Xk,
k = LMII) test score was chosen as the outcome variable and missing values for this test score were simulated.
The accuracy of two models was compared: model 1 estimated the missing data based on the observed part of
the same dataset; model 2 estimated the missing data using a secondary dataset which was joined with the first
dataset. This validation step was also repeated where MMSE represented the outcome variable ( Xk, k = MMSE).
In this validation approach the test dataset was selected from ADNI sub, which was randomly split into a
25% test (missing data) and 75% training (observed data) set used for model 1 (iobs1 ⊆ ADNI ). A second training dataset representing a randomly assigned 75% subsample of the AIBL dataset was generated for model 2
(iobs2 ⊆ AIBL ). As mentioned above, the size of training and test datasets across models 1 and 2 were the same
to ensure fair comparisons between the models. The outcome variable (LMII or MMSE) in the test dataset
(imis ⊆ ADNI ) was simulated as missing; note the same test samples were used for both models. MissForest was
applied to derive estimates of the missing values. The performance of the data imputation was examined on the
test dataset using the mean absolute error (MAE) and the Pearson correlations between the estimated and the
actual scores.
The performance metric, MAE, was calculated as:
MAE =

N

1   actual
imp 
− xi 
xi
N

(1)

i=1
imp
where N is the number observation in the test dataset, xi shows the imputed values, and xiactual the actual value

of the score measured for an observation point i in the test dataset. To measure the variability the analyses were
replicated 100 times. For each replication new A
 DNIsub test and training data sets were randomly generated.
In order to determine if AIBL and ADNI had comparable accuracy at imputing missing data in each other,
the validation was repeated with the test dataset and model 1 training data drawn from AIBL, and with model
2 training data drawn from ADNI.
Second validation approach: to test the limit of efficacy of the proposed method, the impact of varying degrees
of missingness in the test dataset and different sizes of training datasets were evaluated. ADNIsub was used as
the training dataset and the test dataset was set as a randomly selected subset of AIBL equal to 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, and 100% of the AIBL dataset and the outcome variable (LMII or MMSE) was
simulated as missing. To provide variance estimates, this process was replicated 100 times. These analyses were
also repeated for smaller training sets equal to 10% and 50% of participants in ADNIsub (randomly selected).
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AIBL dataset (N = 1791)
Clinical Classification CN/MCI/AD
[N (%)]

ADNI dataset (N = 2122)

1179 (65.83)/296 (16.53)/316 (17.64) 791 (36.95)/962 (41.38)/369 (21.68)

Joined harmonised dataset
(N = 3913)
1970 (50.35)/1258 (32.15)/685
(17.51)

Statistic (df)

p-value

2

< 0.001

2

< 0.001

χ (2) = 408.03

Sex:female [N (%)]

1015 (56.67)

993 (46.80)

2008 (51.32)

χ (1) = 37.53

Years of age at baseline [mean (sd)]

72.42 (7.64)

74.10 (7.26)

72.91 (7.42)

t(3719) = − 3.75

APOE-ε4 allele
0/1/2 [N (%)]

935 (52.21)/449 (25.07)/90 (5.030)

1114 (52.50)/739 (34.83)/194 (9.14)

2049 (52.36)/1188 (30.36)/284 (7.26) χ2(2) = 32.11

Months of follow-up [mean (sd)]

39.98 (35.77)

37.54 (35.72)

38.66 (35.76)

W = 1,961,934

0.077

Years of education < 9/9–12/13–
15/15+ [N (%)]

185 (10.33)/656 (36.63)/345
(19.26)/549 (30.65)

23 (1.08)/288 (13.57)/401
(18.90)/1410 (66.45)

208 (5.32)/944 (24.12)/746
(19.06)/1959 (50.06)

χ2(3) = 619.66

< 0.001

< 0.001
< 0.001

Table 1.  Demographics table for AIBL, ADNI and the joined dataset. p-values present statistical differences
between AIBL and ADNI participants calculate with two-sample t-test for continuous data with normal
distribution, Mann–Whitney U test for continuous data with non-normal distribution, and χ2 testing for
categorical variables).

Data harmonization application. Unmeasured test scores (CVLT-II in ADNI and RAVLT in AIBL) were
imputed using MissForest. The utility of the resulting imputed data was examined by comparing the distribution of the imputed and actual test scores through boxplots stratified by clinical classification (CN, MCI, AD).
Further, the difference between the clinical classifications of both imputed and actual data was evaluated using
Student’s t-tests and Cohen’s d effect sizes. Here, imputed ADNI CVLT-II scores were compared to the observed
AIBL CVLT-II scores and imputed AIBL RAVLT scores were compared to the observed ADNI RAVLT scores.
We also performed sensitivity analysis on CVLT-II and RAVLT scores using their original values in AIBL and
ADNI (Details of this sensitivity analysis are given in the “Supplementary materials”).
Data harmonization utility case study.

The utility of harmonised data to increase power in nuanced
analyses was evaluated by considering the influence of Aβ-amyloid levels on memory performance in APOE
ε4-homozygotes with mild cognitive impairment (a small, specific sample of participants). The associations
between Aβ-amyloid levels and the CVLT-II and RAVLT total immediate recall memory scores in the sample
were evaluated for both the actual and the harmonized datasets using regression analyses.

Results

Significant differences in distribution of clinical classification, sex, APOE ε4 status, level of education as well
as age between AIBL and ADNI were observed, Table 1. Note that due to participant drop-out and enrichment
strategies different participants completed different numbers of e valuations31–33.

Validation results.

The mean absolute errors (MAE; mean ± standard error) of the first validation approach
indicated that the imputed ADNI LMII (range 0–25) and ADNI MMSE (range 0–30) scores estimated using the
observed part of the ADNI dataset were 1.95 ± 0.00 and 1.60 ± 0.00, respectively. The correlation (mean ± standard error) between the imputed values for ADNI LMII and ADNI MMSE scores estimated using the observed
part of the ADNI dataset were 0.91 ± 0.00 and 0.81 ± 0.00, respectively. The MAE (mean ± standard error) for the
imputed ADNI LMII and ADNI MMSE scores estimated using the AIBL dataset were 2.40 ± 0.00 and 2.19 ± 0.00,
respectively. Also, the correlation between ADNI LMII and ADNI MMSE scores estimated using the AIBL dataset were 0.88 ± 0.00 and 0.76 ± 0.00, respectively.
Further, MAE (mean ± standard error) for the imputed AIBL LMII and AIBL MMSE scores using the observed
part of the AIBL dataset, were 1.64 ± 0.00 and 1.31 ± 0.00, respectively. The correlation (mean ± standard error)
between the imputed AIBL LMII and AIBL MMSE scores using the observed part of the AIBL dataset were
0.92 ± 0.00 and 0.88 ± 0.00. The MAE (mean ± standard error) for the estimated AIBL LMII and AIBL MMSE
scores using the ADNI dataset, were 1.65 ± 0.00 and 1.44 ± 0.01, respectively. The correlation (mean ± standard
error) between the imputed AIBL LMII and AIBL MMSE scores using the ADNI dataset, were 0.92 ± 0.00 and
0.86 ± 0.00.
The accuracy of the imputation method was very stable for different sizes of test and training data with the
MAE only varying between 1.62 and 1.73 for LMII and between 1.44 and 1.58 for MMSE (Figs. 1 and 2). Further,
accurate results were still obtained when the training (measured data) set was only 10% of the size of the test
dataset (missing data) with MAEs of 1.73 and 2.52 for LMII and MMSE, respectively. The correlation between
the actual and predicted values for the estimated LMII and MMSE scores showed similar accuracy for the different sizes of test and training datasets, varying between 0.91 and 0.92 for LMII and between 0.84 and 0.87 for
MMSE (Figs. 3 and 4).

Evaluation of imputed unmeasured data. A similarly high level of significant discrimination (p < 0.001)
and large effect sizes (d > 1) between clinical classification was observed for the actual and the imputed scores
of the CVLT-II and RAVLT (Fig. 5). The variance of the imputed variable in each group were comparable to the
observed dataset (Fig. 5). The p-values and effect sizes are reported in Supplementary Tables S2 and S3.
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Figure 1.  Performance of imputed simulated missing AIBL LMII scores with different sizes of training and
missing data: the performance is calculated using the mean absolute error (MAE) of imputed and actual data.
Different size of training data samples of the ADNI dataset (equal to the size of 10%, 50%, and 100% of the
AIBL dataset) and different sizes of simulated missing data samples of 10%, 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, and 100% of the AIBL dataset were used. The results show high prediction accuracy even for training
(reference) dataset with ten times smaller sample size compared to the size of the joining dataset.

Figure 2.  Performance of imputed simulated missing AIBL MMSE scores with different sizes of training and
missing data: the performance is calculated using the mean absolute error (MAE) of imputed and actual data.
Different size of training data samples of the ADNI dataset (equal to the size of 10%, 50%, and 100% of the AIBL
dataset) and different sizes of simulated missing data samples of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, and 100% of the AIBL dataset were used. The results show high prediction accuracy even for a training
dataset with ten times smaller sample size compared to the size of the joining data.

Data harmonisation utility case study. For the harmonized data, a significant negative correlation
between CVLT-II scores and Aβ level in MCI who are APOE-ε4 homozygotes was observed (r = − 0.32, p < 0.001).
No significant correlation was observed in actual AIBL data with the smaller sample size. A significant negative
correlation was observed between RAVLT Total Immediate Recall scores and Aβ level in both the harmonized
and actual ADNI data (r = − 0.32, p < 0.001; r = − 0.30, p < 0.001), refer to Fig. 6.

Discussion

In this study, we have adapted a machine learning method, MissForest, for the harmonization of cognitive test
scores. The method capitalises on the underlying structure and relationships of the datasets provided. Data across
two separate datasets were used to impute data for a test not measured in one of the datasets to align it to a test
measured in the other dataset. Results indicated that the method was successful at imputing data across datasets
that could be combined to provide an overall harmonised dataset.

Scientific Reports |
Vol:.(1234567890)

(2021) 11:23788 |

https://doi.org/10.1038/s41598-021-02827-6

6

www.nature.com/scientificreports/

Figure 3.  Performance of imputed simulated missing AIBL LMII scores with different sizes of training and
missing data: the performance is calculated using the correlation between the imputed and actual data. Different
size of training data samples of the ADNI dataset (equal to the size of 10%, 50%, and 100% of the AIBL dataset)
and different sizes of simulated missing data samples of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and
100% of the AIBL dataset were used. The results show high prediction accuracy even for training (reference)
dataset with 10 times smaller sample size compared to the size of the joining dataset.

Figure 4.  Performance of imputed simulated missing AIBL MMSE scores with different sizes of training
and missing data: The performance is calculated using the correlation between the imputed and actual data.
Different size of training data samples of the ADNI dataset (equal to the size of 10%, 50%, and 100% of the AIBL
dataset) and different sizes of simulated missing data samples of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
90%, and 100% of the AIBL dataset were used. The results show high prediction accuracy even for a training
dataset with ten times smaller sample size compared to the size of the joining data.

Treating unmeasured test scores as missing values and imputing missing scores using values from another
dataset had comparable accuracy when imputing missing data within the same dataset, although accuracy was
slightly higher when imputing using the same dataset. Further, increased accuracy was observed when AIBL
was set as the test dataset in comparison to when ADNI was set as the test dataset. This could be explained by
ADNI having more variability in the data due to a multi-centre collection strategy in comparison to two collection centres run under a central umbrella for AIBL. This may result in a lower ability to extract the underlying
structure and relationships used for driving the imputation method in ADNI. Interestingly, it was shown that the
range of accuracy does not change with different sample sizes for the test datasets, however using a bigger training dataset reflects a slightly improved performance. This is a promising result showing that even small datasets
can be harmonized with larger publicly available datasets such as AIBL and ADNI. Further, it should be noted
that these accurate results were obtained even though there were significant demographic differences between
the AIBL and ADNI datasets, again suggesting that datasets with varying testing protocols can be effectively
harmonised using this strategy.
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Figure 5.  ADNI data imputed: distribution of the actual AIBL CVLT-II Total Immediate Recall scores and
the imputed ADNI CVLT-II Total Immediate Recall scores for each clinical classification. AIBL data imputed:
distribution of the actual ADNI RAVLT Total Immediate Recall score and the imputed AIBL RAVLT Total
Immediate Recall score for each clinical classification.

Application of the method to actual missing data was able to show that imputed missing test scores (RAVLT
in AIBL and CVLT-II in ADNI) and measured test data hold similar significant discrimination between clinical
classifications. Note that clinical classifications of the subjects were not included in the test or training datasets.
The case study also showed that in a very nuanced analysis (of MCI APOE-ε4 homozygotes), a correlation
between Aβ levels and CVLT-II scores, which was not significant for the AIBL study prior to harmonization,
was significant for the joined dataset after harmonisation. This result agrees with previous studies showing an
association between cognitive performance and Aβ levels in MCI individuals41–44.

Strengths of the study. One important strength of the proposed method is the capability of random forest based approaches to handle high dimensional mixed-type d
 ata28. Given that data from studies researching
Alzheimer’s disease include continuous (e.g. age), discrete (e.g. MMSE) and categorical (e.g. gender) random
variables, such a capability is essential for a harmonization method in this field. Secondly, the proposed method
includes the rate of change for each of the clinical and cognitive tests as an input to the MissForest imputation
model. This is important for health care data (e.g. Alzheimer’s data) to capture the temporal patient characteristics inherent in longitudinal measurements for each individual. Another crucial strength of the proposed procedure is that, unlike linear models such as multiple imputation by chained equations ( MICE45), random forest is
a non-parametric method and can handle nonlinearity within the data.
Further, in contrast to latent variable a pproaches21,24 that also use underlying information across d
 atasets26,27,46,
an additional ‘anchor’ dataset(s) that includes both of the unmeasured tests is not required for the method presented here.
Limitations and future directions. The main limitation of the proposed approach is the need for a relatively rich dataset that includes both demographics and cognitive scores meaning that studies would need com-
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Figure 6.  The association between Aβ level and memory performance measured with CVLT-II and RAVLT
total immediate recall memory scores. Harmonized data include AIBL and ADNI data, presented in blue and
black, respectively.
parable data across these domains to undertake the harmonisation strategy. However, most cohort studies in
Alzheimer’s disease research have both demographics and thorough neuropsychological test batteries.
There are two opportunities for improving the proposed method. Firstly, MissForest treats all data as individual data points and does not exploit the inherent structure of longitudinal data within subjects. In the future,
extensions to MissForest (e.g. using mixed-effects random f orest47 for missing data imputation) could be considered to provide improved imputation estimations as well as prognostic estimations into the future. Secondly,
future work should consider the challenges presented by harmonizing more than two datasets, for example the
number of tests to be imputed will exponentially increase with an increasing number of datasets and it will be
necessary to ensure the method is robust in such scenarios.

Summary

In summary, our results suggest using MissForest for data imputation can provide a practical solution for data
harmonization across Alzheimer’s disease cohort studies, specifically AIBL and ADNI. Such harmonized datasets
provide larger sample sizes and increased study power, in turn allowing more nuanced analyses to be undertaken
and leading to improvements in the generalisability of findings.
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